A cost minimisation analysis comparing oral linezolid and intravenous daptomycin administered via an outpatient parenteral antibiotic therapy programme in patients requiring prolonged antibiotic courses

References

• Kieran J, O’Reilly A, Parker J, et al. Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting. Eur J Clin Microbiol. 2009;28(11):1369–1374.
   Google Scholar
• Durojaiye OC, Bell H, Andrews D, et al. Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents. 2018;51(1):26–32.
   PubMed Web of Science ®Google Scholar
• Britt RS, LaSalvia MT, Padival S, et al. Evaluation of inpatient antimicrobial regimens for readmitted outpatient parenteral antimicrobial therapy patients receiving daptomycin or ertapenem for ease of administration. Open Forum Infect Dis. 2019;6(12):ofz496.
   PubMed Web of Science ®Google Scholar
• Vargas-Palacios A, et al. Cost-effectiveness of outpatient parenteral antibiotic therapy: a simulation modelling approach. J Antimicrob Chemother. 2017;72(8):2392–2400.
   PubMed Web of Science ®Google Scholar
• Psaltikidis EM, da Silva EN, Bustorff-Silva JM, et al. Economic evaluation of outpatient parenteral antimicrobial therapy: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. 2017;17(4):355–375.
   Google Scholar
• DImitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9):e049733.
   PubMed Web of Science ®Google Scholar
• Iversen K, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. New England Journal of Medicine. 2018;163(15):415–424.
   Google Scholar
• Li H-K, et al. Oral versus intravenous antibiotics for bone and joint infection. New England Journal of Medicine. 2019;380(5):425–436.
   Google Scholar
• Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. Clin Microbiol Infect. 2020;26(3):299–306.
   PubMed Web of Science ®Google Scholar
• Veve MP, Wagner JL, Kenney RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48(1):56–60.
   PubMed Web of Science ®Google Scholar
• Arnold MR, Wormer BA, Kao AM, et al. Home intravenous versus oral antibiotics following appendectomy for perforated appendicitis in children: a randomized controlled trial. Pediatr Surg Int. 2018;34(12):1257–1268.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Ampofo K, Pavia AT, et al. Comparative effectiveness of oral versus outpatient parenteral antibiotic therapy for empyema. Hosp Pediatr. 2015;5(12):605–612.
   PubMedGoogle Scholar
• Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2007;(4):CD003772.
   Web of Science ®Google Scholar
• Euba G, Murillo O, Fernández-Sabé N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother. 2009;53(6):2672–2676.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203–212.
   PubMed Web of Science ®Google Scholar
• Ager S, Gould K. Clinical update on linezolid in the treatment of gram-positive bacterial infections. Infect Drug Resist. 2012;5(1):87–102.
   PubMedGoogle Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Supplement 4):iv7–iv15.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723–2726.
   PubMed Web of Science ®Google Scholar
• Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. New England Journal of Medicine. 2005;353:2305-2306. doi:10.1056/NEJM200511243532123.
   Google Scholar
• Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clinical infectious disease. 2002;34(12):1651–2.
   Google Scholar
• ZYVOX®Warnings and Precautions (linezolid). Pfizer Medical Information – US; [cited 2022 Jan 06]. Available from: https://www.pfizermedicalinformation.com/en-us/zyvox/warnings.
   Google Scholar
• Patel S, Saw S. Daptomycin. In: Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. 2021. p. 866–907. Boca Raton, Florida, US: CRC press.
   Google Scholar
• Grau D, Clarivet B, Lotthé A, et al. Complications with peripherally inserted Central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6(1). doi:10.1186/s13756-016-0161-0
   PubMedGoogle Scholar
• Liu C, Bayer A, Cosgrove SE, Infectious Diseases Society of America, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55.
   PubMed Web of Science ®Google Scholar
• Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):1–10.
   PubMed Web of Science ®Google Scholar
• McMeekin N, Geue C, Briggs A, OVIVA Orators, et al. Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Res. 2019;4:108.
   PubMedGoogle Scholar
• Wawruch M, Bozekova L, Krcmery S, et al. Cost-effectiveness analysis of switching from intravenous to oral administration of antibiotics in elderly patients. Bratisl Lek Listy. 2004;105(10–11):374–378.
   PubMedGoogle Scholar
• Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47(6):1824–1831.
   PubMed Web of Science ®Google Scholar
• Rege S, Mohr J, Lamp KC, et al. Safety of daptomycin in patients completing more than 14 days of therapy: results from the cubicin® outcomes registry and experience. Int J Antimicrob Agents. 2013;41(5):421–425.
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Shrestha J, Everett A, et al. Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study. J Antimicrob Chemother. 2016;71(2):506–512.
   PubMed Web of Science ®Google Scholar
• ABF. Admitted patient price list - summary; 2020 [cited 2021 Oct 03]. Available from: https://www2.hse.ie/file-library/cross-border-directive/admitted-patient-price-list-summary-inpatient.pdf.
   Google Scholar
• H. Information and Q. Authority. Guidelines for the economic evaluation of health technologies in Ireland; 2020.
   Google Scholar
• Consumer prices monthly series; [cited 2021 Dec 28]. Available from: https://data.cso.ie/.
   Google Scholar
• Purchasing Power Parities for GDP and related indicators; [cited 2021 Dec 28]. Available from: https://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP.
   Google Scholar
• Health Service Executive. Hi tech meds list; 2021. Available from: https://www.hse.ie/eng/staff/pcrs/online-services/hitechmedslist.pdf.
   Google Scholar
• IPHA. Irish Pharmaceutical Healthcare Association price changes; 2016. Available from: https://www.hse.ie/eng/about/who/cpu/iphaprices16/iphapricechanges.pdf.
   Google Scholar
• Sweeney E, Curtin N, de Barra E, et al. National guidelines on the provision of outpatient parenteral antimicrobial therapy (OPAT). Ir Med J. 2020;113(7):123.
   PubMedGoogle Scholar
• Chapman ALN, Patel S, Horner C, et al. Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC-Antimicrob Resist. 2019;1(2):dlz026.
   PubMedGoogle Scholar
• Pay scales - healthservice.ie; [cited 2021 Sep 29]. Available from: https://healthservice.hse.ie/staff/benefits-services/pay/pay-scales.html.
   Google Scholar
• Zhao M, Liang L, Ji L, et al. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. Int J Antimicrob Agents. 2016;48(3):231–238.
   PubMed Web of Science ®Google Scholar
• Chuang Y-C, Wang J-T, Lin H-Y, et al. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis. 2014;14(1). doi:10.1186/s12879-014-0687-9
   Google Scholar
• Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother. 2014;58(2):734–739.
   PubMed Web of Science ®Google Scholar
• Whang DW, Miller LG, Partain NM, et al. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013;57(10):5013–5018.
   PubMed Web of Science ®Google Scholar
• Britt NS, Potter EM, Patel N, et al. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis. 2015;61(6):871–878.
   PubMed Web of Science ®Google Scholar
• Yeager SD, Oliver JE, Shorman MA, et al. Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections. Int J Antimicrob Agents. May 2021;57(5):106329.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Senneville É, Abbas ZG, On behalf of the International Working Group on the Diabetic Foot (IWGDF), et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(S1):S1.
   Google Scholar
• Sawada M, et al. Linezolid versus daptomycin treatment for periprosthetic joint infections: a retrospective cohort study. Journal of Orthopaedic Surgery and Research. 2019;14(1):334.
   Google Scholar
• Theil C, Schmidt-Braekling T, Gosheger G, et al. Clinical use of linezolid in periprosthetic joint infections – a systematic review. J Bone Jt Infect. 2020;6(1):7–16.
   PubMedGoogle Scholar
• Morata L, Tornero E, Martínez-Pastor JC, et al. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother. 2014;69(suppl 1):i47–i52.
   PubMed Web of Science ®Google Scholar
• Feng J, Xiang F, Cheng J, et al. Comparative efficacy and safety of vancomycin, linezolid, tedizolid, and daptomycin in treating patients with suspected or proven complicated skin and soft tissue infections: an updated network meta-analysis. Infect Dis Ther. 2021;10(3):1531–1547.
   PubMed Web of Science ®Google Scholar
• Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg. 2009;79(9):629–635.
   PubMed Web of Science ®Google Scholar
• Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010;15(12):554–563.
   PubMed Web of Science ®Google Scholar
• Wald-Dickler N, Holtom P, Spellberg B, et al. Busting the myth of “static vs cidal”: a systemic literature review. Clin Infect Dis. 2018;66(9):1470–1474.
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS, American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132(15):1435–1486.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273–280.
   PubMed Web of Science ®Google Scholar
• Muñoz P, Rodríguez-Creixéms M, Moreno M, et al. Linezolid therapy for infective endocarditis. Clin Microbiol Infect. 2007;13(2):211–215.
   PubMed Web of Science ®Google Scholar
• Switch to oral antibiotics in gram-negative bacteremia - full text view. ClinicalTrials.gov; [cited 2022 Oct 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT04146922.
   Google Scholar
• Lee IR, Tong SYC, Davis JS, et al. Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial. Trials. 2022;23(1):572.
   Web of Science ®Google Scholar
• Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, for the SABATO Trial Group (with linked authorship to the individuals in the Acknowledgements section), et al. Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials. 2015;16(1):450.
   PubMedGoogle Scholar
• Mackenzie M, Rae N, Nathwani D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. Int J Antimicrob Agents. 2014;43(1):7–16.
   PubMed Web of Science ®Google Scholar